Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma
- PMID: 32205655
- PMCID: PMC8059069
- DOI: 10.1097/IIO.0000000000000308
Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma
Conflict of interest statement
The authors declare that they have no conflicts of interest to disclose.
Figures


Similar articles
-
[Palpebral and conjunctival tumors treated by hematoporphyrin-laser therapy].Zhonghua Yan Ke Za Zhi. 1987 Jul;23(4):206-8. Zhonghua Yan Ke Za Zhi. 1987. PMID: 3127160 Chinese. No abstract available.
-
Efficacy of immune checkpoint inhibitors in different types of melanoma.Hum Vaccin Immunother. 2021 Jan 2;17(1):4-13. doi: 10.1080/21645515.2020.1771986. Epub 2020 Jul 14. Hum Vaccin Immunother. 2021. PMID: 32663057 Free PMC article.
-
Targeted Biological Drugs and Immune Check Point Inhibitors for Locally Advanced or Metastatic Cancers of the Conjunctiva, Eyelid, and Orbit.Int Ophthalmol Clin. 2019 Spring;59(2):13-26. doi: 10.1097/IIO.0000000000000271. Int Ophthalmol Clin. 2019. PMID: 30908276 Review. No abstract available.
-
Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.Ophthalmic Plast Reconstr Surg. 2021 Jan-Feb 01;37(1):e9-e13. doi: 10.1097/IOP.0000000000001700. Ophthalmic Plast Reconstr Surg. 2021. PMID: 32618825 Free PMC article.
-
Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma.Int Ophthalmol Clin. 2019 Spring;59(2):53-63. doi: 10.1097/IIO.0000000000000263. Int Ophthalmol Clin. 2019. PMID: 30908279 Review. No abstract available.
Cited by
-
Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.J Ophthalmic Vis Res. 2022 Aug 15;17(3):405-412. doi: 10.18502/jovr.v17i3.11579. eCollection 2022 Jul-Sep. J Ophthalmic Vis Res. 2022. PMID: 36160103 Free PMC article. Review.
-
Targeting β-catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression.Int J Pharm. 2023 Jun 10;640:123043. doi: 10.1016/j.ijpharm.2023.123043. Epub 2023 May 11. Int J Pharm. 2023. PMID: 37172631 Free PMC article.
-
Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches.Pathol Oncol Res. 2025 Aug 4;31:1612085. doi: 10.3389/pore.2025.1612085. eCollection 2025. Pathol Oncol Res. 2025. PMID: 40831998 Free PMC article. Review.
-
Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.Ophthalmic Plast Reconstr Surg. 2023 Sep-Oct 01;39(5):e152-e155. doi: 10.1097/IOP.0000000000002407. Epub 2023 May 16. Ophthalmic Plast Reconstr Surg. 2023. PMID: 37207285 Free PMC article.
References
-
- Shields CL, Chien JL, Surakiatchanukul T, et al. Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes—The 2017 J. Donald M. Gass Lecture. Asia Pac J Ophthalmol (Phila). 2017;6:109–120. - PubMed
-
- Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969-1991. Acta Ophthalmol (Copenh). 2009;70:289–296. - PubMed
-
- Esmaeli B Patterns of regional and distant metastasis in patients with conjunctival melanoma Experience at a cancer center over four decades. Ophthalmology. 2001;108:2101–2105. - PubMed
-
- Vaziri M, Buffam FV, Martinka M, et al. Clinicopathologic features and behavior of cutaneous eyelid melanoma 1 1. Ophthalmology. 2002;109:901–908. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical